The HPLC method for the determination of sotalol (SOT), metoprolol (MET) and a-hydroxymetoprolol metabolite (MET-H), paracetamol (PAR), paracetamol glucuronide (PAR-G) and paracetamol sulfate (PAR-S) in human urine is described. Analyses were carried out on a reversed-phase LiChroCART ® Purospher ® C18e column (125 mm×3 mm, 5 mm particles) (Merck) with gradient elution as well as spectrophotometric and fluorometric detection. Good resolution of the analyzed substances was obtained within a time range of no longer than 15 min. The linearity ranges of the callibration curves in human urine (as matrix) were: 3.25 -45 mg ml -1 (SOT), 0.75 -40 mg ml -1 (MET), 0.6 -40 mg ml -1 (MET-H), 4.6 -60 mg ml -1
Introduction
mortem fluids and tissue samples by LC/APCI-MS. 15 PAR is metabolized primarily in the liver, where its major b-Blockers are a class of drugs used for various indications, but metabolites include inactive sulfate (PAR-S) and glucuronide particularly for the management of cardiac arrhythmias and (PAR-G) conjugates, which are excreted by the kidneys. Only a cardioprotection after myocardial following infarction. Patients small amount is metabolized via the hepatic cytochrome enzyme who take b-adrenergic blocking agents (e.g. metoprolol, sotalol), system, which is responsible for the toxic effects of paracetamol. often require b-blockers administration together with drugs from Figure 2 presents basic routes of PAR metabolism. other therapeutic groups (e.g. analgesics). The most often PAR and its metabolites were determined by HPLC-MS, 19 CE administered analgesics are non-prescribed pharmaceuticals with MS 20 or UV 21 detection, HPLC-DAD [22] [23] [24] [25] [26] or evaporative light containing paracetamol as an active ingredient.
scattering detector (ELSD).
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A chromatographic system for Therefore, a simple method for the simultaneous determinations analyzing PAR in the presence of 10 other drugs (imipenem, of sotalol (SOT), metoprolol (MET), a-hydroxymetoprolol dipyrone, vancomycin, amikacin, cefazolin, fluconazole, (MET-H), paracetamol (PAR), paracetamol glucuronide (PAR prednisolone, dexamethasone, furosemide, ketoprofen) was G), and paracetamol sulfate (PAR-S) is needed.
SOT (Fig. 1) is a b-blocker with II and III class antiarrhythmic properties. 1, 2 It shows no pharmacokinetic interactions, is not metabolized and is entirely excreted by the kidneys. In most patients, a therapeutic response is obtained at a total daily dose of 160 to 320 mg/day, but some patients with life-threatening refractory ventricular arrhythmias may require doses as high as 480 -640 mg/day. 2 MET is a selective b1-receptor blocking agent that can be used alternatively to SOT, and is additionaly used in migraine prevention. 3, 4 MET is metabolized in 85% with MET-H as a main metabolite. 5 SOT and MET can be detected in urine, 5-9 plasma 10-14 and post mortem body fluids. 15, 16 As prohibited doping agents, the SOT and MET concentrations were measured by LC-TOFMS in the urine of athletes. 17 MET and its metabolites concentration have been measured by CE, 5 HPLC with FL detection, 7, 13 and HPLC-MS. 18 MET in the † To whom correspondence should be addressed. proposed.
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A method for the simultaneous RP-HPLC determination of b-adrenergic blocking agents with PAR and its metabolites has not been proposed in the literature.
Experimental

Chemicals and solutions
Paracetamol (99% purity) was obtained from Fluka BioChemika (Darmstadt, Germany); paracetamol sulfate sodium salt, paracetamol glucuronide sodium salt, sotalol hydrochloride and metoprolol tartrate salt were purchased from Sigma-Aldrich (Schnelldorf, Germany) (97 -98% purity). a-Hydroxymetoprolol (98% purity) was bought from Toronto Research Chemicals (North York, Canada). Acetonitrile, methanol and sodium hydroxide, all of analytical grade, were bought from POCH S.A. (Gliwice, Poland).
Acetonitrile, methanol, water and trifluoroacetic acid (HPLC grade) were purchased from Merck (Darmstadt, Germany). Stock solutions for PAR, PAR-G, PAR-S, SOT, MET and MET-H were prepared by dissolving a specified amount of drug salts in 10 ml of a methanol-water mixture (50:50 v/v) to achive a 1 mg ml -1 concentration of the drug. After preparation, standard solutions were stored at 4˚C and were stable for at least 3 months.
Apparatus
A reversed-phase HPLC system containing a Model L-6200A Intelligent Pump (Merck-Hitachi), a Model L-4500A (MerckHitachi) diode array detector, an L-7480 fluorescence detector, a column oven (Model L-736 Lachrom ® Merck), and a reversedphase LiChroCART ® Purospher ® C18e column (125 mm×3 mm, 5 mm particles) (Merck) with precolumn LiChroCART ® LiChrospher ® C18 (4 mm×4 mm, 5 mm particle size) (Merck) was used. Human urine samples were centrifuged using a HERMLE 323K (Germany) centrifuge. Samples were injected by a Rheodyne valve with a 20-ml loop. Data acquisition was performed on an HPLC System Manager HSM D-7000, Ver. 2.1 (Merck-Hitachi). The accuracy of collected values was 0.01 min for a retention time and 0.0001 for the absorbance scale.
Chromatographic analysis
Elution of analyzed substances from chromatographic columns was carried out at room temperature (22˚C) with gradient elution. The most optimal time of analysis and the separation of analyzed drugs and metabolites was obtained using gradient elution with a mobile phase containing 0.05% trifluoroacetic acid in water (solvent A), methanol (solvent B) and acetonitrile (solvent C).
The gradient elution program is presented in Table 1 . Eluate was monitored by a DAD detector in the range 200 -450 nm. PAR, PAR-G and PAR-S were measured at 243 nm; SOT, MET and MET-H at 227 nm. SOT and MET were also determined by a fluorescence detector without derivatization (Ex, 230 nm; Em, 340 nm).
The limits of detection (LOD) were established as a signal-to noise ratio (S/N) of 3. The limits of quantification were established by multiplying the LOD values 3 times (LOQ = 3×LOD). The specified wavelengths used for the analysis, retention times, LOD and LOQ values are presented in Table 2 .
Sample preparation
Urine samples were prepared according to procedure established for the determination of PAR in the presence of 10 other drugs, but without b-blockers. 22 Human urine collected 4 h after drugs administration was stored at -18°C until needed; 0.5 mL of urine was placed into a 10-ml volumetric flask. Then, 1.5 ml of methanol and 1.5 ml of acetonitrile were added. To the obtained solution, 1 M NaOH was added to achive the desired pH (e.g. 8) and completed to the 
Results and Discussion
A novel chromatographic system was developed. Different chromatographic conditions (columns, gradient composition, flow rates) were tested to obtain the optimal separation of drugs in the shortest time. Under the presented chromatographic conditions (Table 1) , SOT, MET, MET-H, PAR, PAR-S and PAR-G peaks were well separated. The retention times after mobile-phase optimization are presented in Table 2 . 
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Drug identification was performed by comparing the retention times of drugs in a standard solution with the retention times from urine. Also, a standard addition method and a comparison with the absorption spectra of standards were used for substance identification.
The presented method allows the identification of SOT or MET and its a-hydroxy metabolite together with PAR, PAR-S and PAR-G in human urine, which has not been described before.
Obtained chromatograms are presented in Figs. 3 and 4 . Calibration curves were established as a linear function y = ax + b where x is the concentration of the selected drug (mg ml -1 ) in a standards mixture, and y is the detector response (peak area). The values of a and b are constants. The parameters of the calibration curves and the linearity ranges are given in Table 3 .
Calibration solutions were prepared in the concentration range that was expected to be found in urine samples by spiking previously prepared blank urine with a known amount of standards. The examined concentration ranges were subsequently: 1 -60 mg ml -1 (SOT), 0.2 -50 mg ml -1 (MET), 0.1 -50 mg ml -1
(MET-H), 1 -49 mg ml -1 (PAR), 1 -65 mg ml -1 (PAR-G), 1 -60 mg ml -1 (PAR-S). The linearity ranges for the standards in human urine were: 3.25 -45 mg ml -1 (SOT), 0.75 -40 mg ml -1 (MET), 0.6 -40 mg ml -1 (MET-H), 1.95 -45 mg ml -1 (PAR), 4.6 -60 mg ml -1 (PAR-G), 4.95 -50 mg ml -1 (PAR-S). The PAR, PAR-S, PAR-G, SOT and MET-H concentrations can be measured directly in diluted samples by a DAD detector. In the case of MET, which is strongly metabolized (85% of MET is discharged as metabolites), the use of a fluorescence detector is recommended. The concentration ranges of examined drugs in urine after the administration of 500 mg of PAR or 80 mg of a MET tablet to patients (counted to 1 ml of undiluted urine) were: 150 -280 mg ml -1 for PAR-S, 240 -350 mg ml -1 for PAR-G, For an apparatus equiped with a fluorescence detector, this method allows the quantification of very low concentrations of SOT and MET (20 ng ml -1 ), which is useful, since only low percents of drugs are renally excreted in an unchanged form.
Conclusion
Methods that allow screening of drug and metabolite concentrations in body fluids could be helpful in a pharmacogenic study allowing an evaluation of how an individual's genetic inheritance affects the body's response to drugs. Using this analytical procedures, current drug administration based on the weight or age of patients can be replaced by methods based on personal drug metabolism and excretion.
